利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤的疗效观察

宾燕成; 张华; 李虎生; 冯翠; 吕钊

doi:10.13201/j.issn.1004-2806.2015.09.008

利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤的疗效观察

- 1 广西玉林市红十字会医院血液科(广西玉林, 537000)

详细信息

通讯作者: 宾燕成,E-mail:binyancheng1980@163.com

中图分类号: R733.4

收稿日期: 2015-02-03

Observation of the curative effect of rituximab combined with GDP regimen in the treatment of recurrent and refractory diffuse large B-cell lymphoma

- Department of Hematology, Guangxi Yulin City Red Cross Hospital, Yulin, 537000, China

More Information

Corresponding author: BIN Yancheng, E-mail: binyancheng1980@163.com

Received Date: 03 February 2015

摘要

摘要: 目的:观察利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法:2009-01-2013-12在我院住院的复发难治性DLBCL患者28例,采用利妥昔单抗联合GDP方案化疗(利妥昔单抗375 mg/m² d0,吉西他滨1 000 mg/m² d1、8,顺铂25 mg/m² d1~3,地塞米松40 mg/d d1~4),21 d为一个疗程。完成2个疗程后评价疗效及不良反应。结果:随访9~58个月,28例患者中13例获得完全缓解,9例获得部分缓解,1例疾病稳定,5例疾病进展,总有效率为78.6%;常见的不良反应为骨髓抑制和胃肠道反应。结论:利妥昔单抗联合GDP方案是治疗复发难治性DLBCL一个安全有效的挽救方案。
- 淋巴瘤,大B细胞,弥漫性 /
- 利妥昔单抗 /
- GDP
Abstract: Objective:To explore the effect of rituximab combined with GDP regimen in the treatment of recurrent and refractory diffuse large B-cell lymphoma (DLBCL) and adverse effect.Method:A total of 28 cases of refractory and relapsed DLBCL from January 2009 to December 2013 in our hospital,we used the combination of rituximab and GDP chemotherapy (rituximab 375 mg/m² d0,gemcitabine 1000 mg/m² d1,8,cisplatin 25 mg/m² d1-3,dexamethasone 40 mg/d d1-4),21 days for a course of treatment.Curative effect and adverse reaction evaluation completed after two courses.Result:Followed up for 9-58 months,13 cases achieved complete remission,9 cases achieved partial remission,1 patients with stable disease,5 patients with disease progression,the total efficiency was 78.6%.Common adverse reactions were myelosuppression and gastrointestinal tract reaction.Conclusion:Rituximab combined with GDP is a safe and effective saving scheme for relapsed refractory DLBCL.
- diffuse large B-cell lymphoma /
- rituximab /
- GDP

HTML全文

参考文献(10)

[1]	王潇潇,黄慧强,夏忠军,等.利妥昔单抗联合挽救化疗治疗复发或难治弥漫大B细胞性非霍奇金淋巴瘤的长期随访结果[J].南方医科大学学报,2010,30(4):867-874.
[2]	张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:220-227.
[3]	孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2008:34-35.
[4]	Sabattini E,Bacci F,Sagramoso C,et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica,2010,102:83-87.
[5]	Pfreundschuh M,Kuhnt E,Trumper L,et al.CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J].Lancet Oncol,2011,12:1013-1022.
[6]	Récher C,Coiffier B,Haioun C,et al.Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma(LNH03-2B):an open-label randomised phase 3 trial[J].Lancet,2011,378:1858-1867.
[7]	Friedberg JW.Relapsed/refractory diffuse large B-cell lymphoma[J].Hematology Am Soc Hematol Educ Program,2011,2011:498-505.
[8]	王梅,李永梅,傅国平,等.GDP方案治疗难治或复发弥漫性大B细胞非霍奇金淋巴瘤疗效分析[J].中华肿瘤防治杂志,2010,17(6):452-454.
[9]	刘永钟,梁淑仪,彭杰文,等.GDP方案治疗复发和难治性弥漫性大B细胞淋巴瘤的疗效分析[J].中国肿瘤临床与康复,2011,18(6):519-522.
[10]	郭晔,陈瑜,洪小南,等.R-ICE挽救方案治疗复发弥漫大B细胞淋巴瘤患者的临床Ⅱ期多中心研究[J].中华血液学杂志,2014,35(4):314-317.